Imaging Agent for Bladder Cancer Okayed

Share this article:

The FDA has approved Cysview (hexaminolevulinate HCl), an optical imaging agent indicated for use in the cystoscopic detection of non-muscle-invasive papillary bladder cancer in patients suspected or known to have lesions on the basis of prior cystoscopy.

Cysview is used with the Karl Storz D-Light C Photodynamic Diagnostic System to perform cystoscopy with the blue light setting (mode 2) as an adjunct to the white light setting (mode 1).

Cysview is injected into the bladder through a catheter. It accumulates differentially in malignant cells. When illuminated with blue light from the cystoscope, the cancerous lesions fluoresce red, highlighting the malignant areas.

GE Healthcare, a unit of General Electric Company, has licensed Cysview from Photocure ASA, a Norwegian pharmaceutical company.

Share this article:
You must be a registered member of RUN to post a comment.

More in FDA News

FDA to Lift Restrictions on Avandia for Diabetes

FDA to Lift Restrictions on Avandia for Diabetes

Not all experts are happy with granting wider access to the troubled medication, however.